Armodafinil in the treatment of excessive sleepiness

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 993-1002

  Bogan, Richard K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Armodafinil; Excessive sleepiness; Jet lag disorder; Modafinil; Narcolepsy; Obstructive sleep apnea; Shift work disorder

Indexed keywords

AMPHETAMINE; ARMODAFINIL; CYTOCHROME P450; DEXAMPHETAMINE; MODAFINIL; OXYBATE SODIUM; PLACEBO;

AGGRESSION; AGITATION; ANXIETY; AREA UNDER THE CURVE; CARDIOVASCULAR SYMPTOM; CATAPLEXY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELUSION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HALLUCINATION; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; JET LAG; MANIA; MAXIMUM PLASMA CONCENTRATION; NARCOLEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLEEP WAKING CYCLE; SOMNOLENCE; SUICIDAL IDEATION; WAKEFULNESS; XEROSTOMIA;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; SLEEP; TREATMENT OUTCOME; WAKEFULNESS;

EID: 77949902563     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003705738     Document Type: Review

References (54)

1. National Sleep Foundation. 2008 Sleep in America Poll. National Sleep Foundation, Washington, DC; 2008. Available from: http://www. sleepfoundation.org/category/article-type/sleep-america-polls. [Last accessed 1 November 2009]
2. National Sleep Foundation. 2009 Sleep in America Poll. National Sleep Foundation, Washington, DC; 2009. Available from: http://www. sleepfoundation.org/category/article-type/sleep-america-polls. [Last accessed 1 November 2009]
3. Black J, Duntley SP, Bogan RK, O'Malley MB. Recent advances in the treatment and management of excessive daytime sleepiness. CNS Spectr 2007;12:1-14
4. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235
5. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007;30:711-719
6. Richardson GS. The human circadian system in normal and disordered sleep. J Clin Psychiatry 2005;66(Suppl 9):3-9
7. Schwartz JR, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs 2006;66:2357-2370
8. Eastman CI, Stewart KT, Mahoney MP, et al. Dark goggles and bright light improve circadian rhythm adaptation to night-shift work. Sleep 1994;17:535-543
9. Morgenthaler TI, Lee-Chiong T, Alessi C, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007;30:1445-1459
10. Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004;27:1453-1462
11. Waage S, Moen BE, Pallesen S, et al. Shift work disorder among oil rig workers in the North Sea. Sleep 2009;32:558-565
12. Bogan R, Tiller J, Youakim J, Roth T. Armodafinil for excessive sleepiness associated with jet lag disorder. Sleep 2009;32(Suppl):A52
13. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-1035
14. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-1711
15. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
16. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
17. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1:391-397
18. US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49
19. US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-123
20. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415-421
21. Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003;124:2192-2199
22. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005;353:476-486
23. Erman MK, Rosenberg R, for the US Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry 2007;9:188-194
24. Coste O, Lagarde D. Clinical management of jet lag: what can be proposed when performance is critical? Travel Med Infect Dis 2009;7:82-87
25. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009;373:482-491
26. Cephalon Inc. NUVIGIL™ (armodafinil) tablets (C-IV). Frazer, PA: Cephalon, Inc., 2008. Available from: http://www.nuvigil.com/media/ Full-Prescribing-Information.pdf. [Last accessed 23 September 2009]
27. Beck P, Odle A, Wallace-Huitt T, et al. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31:1647-1654
28. Urbano FJ, Leznik E, Llinas RR. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci USA 2007;104:12554-12559
29. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996;93:14128-14133
30. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
31. Fiocchi EM, Lin YG, Aimone L, et al. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol Biochem Behav 2009;92:549-557
32. Cirelli C, Tononi G. On the functional significance of c-fos induction during the sleep-waking cycle. Sleep 2000;23:453-469
33. Espana RA, Scammell TE. Sleep neurobiology for the clinician. Sleep 2004;27:811-820
34. Wisor JP, Dement WC, Aimone L, et al. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85:492-499
35. Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009;29:87-100
36. Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009;29:613-623
37. Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig 2009;29:601-612
38. Robertson PJ, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-137
39. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39:281-288
40. Darwish M, Kirby M, Robertson PJ, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008;47:61-74
41. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22:159-167
42. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnoea/hypopnoea syndrome. Respir Med 2007;101:616-627
43. Roth T, Rippon GA, Arora S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath 2008;12:53-62
44. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-774
45. Roth T, White D, Schmidt-Nowara W. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCAP-adherent adults. Clin Ther 2006;28:689-706
46. Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc 2009;84:958-972
47. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95-102
48. Cephalon, Inc. PROVIGIL (modafinil) tablets. Frazer, PA Cephalon, Inc., 2007. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/ 2007/020717s020s013s018lbl.pdf. [Last accessed 28 September 2009]
49. National Institutes of Health. ClinicalTrials.gov. US National Library of Medicine, Bethesda, MD; 2009. Available from www.clinicaltrials. gov. [Last accessed 14 December 2009]
50. Bixler EO, Vgontzas AN, Lin HM, et al. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab 2005;90:4510-4515
51. Newman AB, Foster G, Givelber R, et al. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005;165:2408-2413
52. Elwood P, Hack M, Pickering J, et al. Sleep disturbance, stroke, and heart disease events: evidence from the Caerphilly cohort. J Epidemiol Community Health 2006;60:69-73
53. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994;17:84-93
54. Flatley D, Reyner LA, Horne JA. Sleep-related crashes on sections of different road types in the UK (1995-2001). Report no. 52. Department of Transport, Road Safety Research, London; 2004